Press Releases
Fluxion Biosciences Launches the F1 Giga-Ohm Seal Plates for the IonFlux System
Fluxion Biosciences announced that it has introduced F1 giga-ohm seal plates for the IonFlux automated patch clamp system. The newly launched F1 plates complement Fluxion’s...
Press Releases
Cytheris announces interim results from ECLIPSE II Hepatitis C multicenter study of IL-7 in chronically infected genotype one and four nonresponders to standard of...
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim...
Press Releases
FDA Approves ERBITUX for First-Line Recurrent Locoregional or Metastatic Head and Neck Cancer in Combination with Platinum-based Chemotherapy with 5-Fluorouracil
Eli Lilly and Company and Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has approved ERBITUX® (cetuximab), in combination with platinum-based...
Press Releases
Trophos initiates phase II proof of concept study for novel cardioprotective compound, TRO40303, in acute myocardial infarction
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces...
Press Releases
Hybrigenics’ specific inhibitor of Ubiquitin-Specific Protease 7 (USP7) is cytotoxic for chronic lymphocytic leukaemia (CLL) cells in vitro
Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases, today...
Press Releases
Cytheris to present interim data from ECLIPSE II Hepatitis C multicenter study at AASLD annual meeting
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim...
Press Releases
Trophos hosts round-table meetings at ECTRIMS to design POC trial to treat progression in multiple sclerosis
Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.